Kibow Biotech Inc. is Pleased to Support World Kidney Day with its Innovative "Enteric Dialysis" Technology in Modulating the "Gut Microbiome with Pro/Prebiotics" Using its Dietary Supplement Product "Renadyl"

NEWTOWN SQUARE, Pa., March 11, 2016 /PRNewswire/ -- "World Kidney Day is a global awareness campaign aimed at raising awareness on the importance of our kidneys. World Kidney Day aims to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. World Kidney Day comes back every year. All across the globe many hundred events take place from public screenings in Argentina to Zumba marathons in Malaysia. We do it all to create awareness. Awareness about preventive behaviors, awareness about risk factors, and awareness about how to live with a kidney disease. We do this because we want kidney health for all." (For more information, please refer to http://www.worldkidneyday.org/about/world-kidney-day/).

Kibow Biotech, Inc. is pleased to join this global awareness campaign by joining and increasing awareness and understanding on its "Enteric Dialysis™ or Uremic Toxin Reduction Technology" concept. The company's technology is based on modulating the Gut Microbiome with its dietary supplement product made with specific strains of Probiotics and selected Prebiotics towards modulation and stabilization of the GUT MICROBIOME and thus improve DYSBIOSIS and also help maintain a healthy kidney function. The company's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials have been published in peer reviewed scientific/medical journals (http://www.kibowbiotech.com/rd/).

Renadyl™ is currently sold via Kibow's own online store (www.renadyl.com or www.kibowbiotech.com). This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA. In addition to marketing and sales of Renadyl™ as a dietary supplement, the company is also exploring the option of advancing the product to a prescription drug status by way of adhering to all USFDA guidelines. This will mandate obtaining the needed Investigator New Drug (IND) process and accomplishing several additional human Randomized Controlled Trials (RCT) in the forthcoming years in USA and possibly in several other countries. As a prescription drug, the product will gain greater awareness and recognition by consumers and healthcare professionals worldwide.

About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor & Media Contact:

N. Ranganathan
(610) 353-5130 or Email

SOURCE Kibow Biotech Inc.

Related Links

http://www.kibowbiotech.com